Written by Klarity Editorial Team
Published: Sep 14, 2025

Key takeaway: Anxiety-driven insomnia creates a reinforcing cycle where poor sleep worsens anxiety and anxiety worsens sleep. In 2026, clinical evidence has strengthened for several medications used to break this cycle, including hydroxyzine, low-dose quetiapine, and mirtazapine. Treatment choice depends on your specific symptoms and health history; a licensed provider can help you find the right approach.
Struggling to sleep because of anxiety? Klarity connects you with licensed providers for same-day online appointments — many insurance plans may cover your visit. See if you may qualify →
Staring at the ceiling at 3 AM, watching minutes tick by while your mind races—this scenario is all too familiar for those trapped in the cycle of insomnia and anxiety. When sleep becomes elusive, with some individuals surviving on just 2-3 hours per night, the quest for solutions becomes desperate. Recent evidence suggests that treating underlying anxiety may be key to resolving certain types of insomnia, particularly sleep maintenance issues. This article explores how anxiety treatments can break the insomnia cycle by addressing the root cause: anxiety itself.
The relationship between anxiety and sleep disturbance creates a vicious cycle that many find impossible to break. Anxiety triggers heightened alertness, racing thoughts, and physical tension. Poor sleep then exacerbates anxiety symptoms the following day, creating a downward spiral.
‘Sleep anxiety’ refers to the specific worry about not sleeping well, which paradoxically makes sleep even more difficult to achieve. This phenomenon often manifests as intrusive thoughts about not getting enough sleep, worrying about the consequences of insomnia, physical tension and restlessness when trying to fall asleep, and hyperawareness of time passing during the night.
Selective Serotonin Reuptake Inhibitors (SSRIs) like sertraline (Zoloft) are primarily prescribed for anxiety and depression, not insomnia. However, many patients report significant sleep improvements once their anxiety is managed effectively. Those suffering from severe sleep maintenance insomnia often see dramatic improvements with consistent SSRI treatment as anxiety levels decrease over weeks or months.
The timing of medication can significantly impact sleep outcomes. SSRIs like sertraline may work better for some when taken in the morning, while others find evening dosing more effective. Starting at lower doses may minimize initial side effects that could temporarily worsen sleep. Consistency in medication timing appears crucial regardless of when you take it.
The pharmacological toolkit for anxiety-driven insomnia has received meaningful updates in 2026 research. Three agents are seeing increased use in this specific patient population: hydroxyzine, low-dose quetiapine, and mirtazapine. Each works through a different mechanism, and selection depends on the patient’s primary symptoms, comorbidities, and medication history.
Hydroxyzine (Vistaril/Atarax), an antihistamine with anxiolytic properties, has accumulated robust real-world evidence by 2026 as a first-line option for anxiety-driven insomnia. It is non-habit-forming, begins working within 30 to 60 minutes, and has a favorable safety profile for most adults. Typical doses for sleep-anxiety overlap range from 25 to 50 mg at bedtime. 2025 and 2026 observational data from large telehealth platforms support its effectiveness in patients who have not responded well to melatonin or behavioral interventions alone.
Low-dose quetiapine (Seroquel), used off-label for insomnia in doses far below its antipsychotic range (12.5 to 50 mg at bedtime), has been studied in several 2024 and 2025 randomized trials for patients with anxiety-driven insomnia who have not responded to first-line options. While effective for sleep onset and maintenance, its metabolic side effect profile warrants careful patient selection. It is typically reserved for cases where anxiety-insomnia overlap is severe and other options have been tried.
Mirtazapine, an antidepressant with strong sedating and anxiolytic properties at lower doses, is increasingly used in 2026 for patients with both depression, anxiety, and insomnia. At 7.5 to 15 mg, its sedating effects are typically most pronounced, making it a practical option for patients who need treatment across multiple symptom domains. Coverage varies by plan. Verify your benefits before booking.
There is no single best medication; treatment depends on your individual symptoms, health history, and other medications. Hydroxyzine is often used as a first-line option due to its non-habit-forming profile. Low-dose quetiapine and mirtazapine may be considered when other options have not been sufficient. A licensed provider should guide this decision.
Yes. Hydroxyzine has antihistamine and anxiolytic properties that make it useful for patients whose insomnia is driven by anxiety. It is non-habit-forming and typically works within 30 to 60 minutes. It may not be suitable for everyone; discuss it with your provider.
Yes. Anxiety-driven hyperarousal is one of the most common causes of chronic insomnia. The cycle is self-reinforcing: anxiety prevents sleep, poor sleep worsens anxiety, and the anxiety about not sleeping compounds the problem. Breaking this cycle often requires addressing both conditions simultaneously.
Cognitive Behavioral Therapy for Insomnia (CBT-i) is the first-line non-medication treatment for insomnia and has strong evidence for anxiety-related sleep problems. Stimulus control, sleep restriction, and relaxation techniques are core components. CBT-i is often recommended alongside medication for best results.
Yes. Klarity’s licensed providers offer same-day online appointments for insomnia and anxiety treatment. Many insurance plans may cover your visit. See if you may qualify for covered care.
Find the right provider for your needs — select your state to find expert care near you.